Last reviewed · How we verify
Maalox
At a glance
| Generic name | Maalox |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Famotidine and Antacids for Treatment of Dyspepsia (PHASE4)
- Effects of Photobiomodulation (PBM) on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients (PHASE4)
- Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders (PHASE2)
- Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders (PHASE2)
- A Study to Evaluate a New Tablet Formulation of Lu AG06466 in Healthy Participants (PHASE1)
- A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults (PHASE1)
- Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects (PHASE1)
- Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Maalox CI brief — competitive landscape report
- Maalox updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI